Merck Sharp & Dohme Animal Health Completes Acquisition of Leyland Animal Health Aquatic Business

July 15, 2024  Source: drugdu 65

"/Rowe, NJ, USA, July 9, 2024 - Merck Sharp & Dohme (Merck is the corporate trading name of Merck & Co. of Rowe, NJ, USA) announced today that its Animal Health division has completed the acquisition of the aquatic business of Gift Blue Animal Health. The acquisition strengthens Merck Sharp & Dohme Animal Health's position in the aquaculture industry, enabling it to promote fish health, welfare and sustainability across all aspects of aquaculture, conservation and fisheries.

Rick DeLuca, President of Mercer Animal Health, said: "With the completion of this acquisition, we are well positioned in the aquaculture industry with a strong and comprehensive portfolio of products covering warm water aquaculture, cold water aquaculture, vaccines, antiparasitic treatments, water conditioners and nutritional supplements. We are excited to welcome our new colleagues to Merck Sharp & Dohme Animal Health and look forward to working together towards our shared goal of 'Science for Healthier Animals™'."

The acquisition brings innovative products such as CLYNAV*, a next-generation DNA-based vaccine that protects Atlantic salmon against pancreatic diseases, IMVIXA*, an anti-parasitic sea lice treatment, and a range of products for warm-water aquaculture production, which complement Merck Shaw Animal Health's existing global vaccine portfolio.

The use of aquatic biochemicals, vaccines, and nutritional supplements is increasing as the demand for protein, food safety, quality food supply, and public health protection continues to grow.


https://mp.weixin.qq.com/s?__biz=MjM5ODI4OTI2NA==&mid=2651974802&idx=1&sn=52d2f6396b44008bfcaa277247eedf3a&chksm=bd28468d8a5fcf9b7bb60496935ac1ba86685825a24f1f0d7213ec387ca450ce1433191206c2&mpshare=1&scene=1&srcid=07126LE2WLOelGQIhwF7zs5H&sharer_shareinfo=e2e31c254f67cec10fd3facbad3e9c5d&sharer_shareinfo_first=e2e31c254f67cec10fd3facbad3e9c5d#rd

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.